First Tracks Biotherapeutics
TRAX
31.46
+0.87
+2.84%
First Tracks Biotherapeutics
US · TRAX
#3189 by market cap
Listed 2026
31.46
+0.87
+2.84%
Live - 5344 symbols - heartbeat 340s ago
· 2026-10-08 10:00
Pre-market
32.45
+6.08%
After-hours
29.99
-1.96%
Overnight
31.57
+3.20%
- Market cap
- 1.12B
- P/E (TTM)i
- -6.94
- P/Bi
- 6.66
- EPSi
- -4.92
- Div yieldi
- 0.00%
- 52W posi
- 48%
Reader sentiment
Are you bullish or bearish on TRAX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2023 | 2024 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 20.87M | 28.76M |
| Research & development | 97.59M | 152.35M |
| Operating profit | -118.46M | -181.10M |
| Pretax profit | -106.15M | -163.71M |
| Tax | -- | -- |
| Net profit | -106.15M | -163.71M |
| Basic EPS | -3 | -5 |
| Diluted EPS | -3.05 | -4.71 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 9.82M | 6.63M | 18.86M | 9.29M |
| Research & development | 41.47M | 39.27M | 33.96M | 25.64M |
| Operating profit | -51.28M | -45.90M | -52.81M | -34.94M |
| Pretax profit | -47.20M | -42.45M | -50.48M | -33.37M |
| Tax | -- | -- | -- | -- |
| Net profit | -47.20M | -42.45M | -50.48M | -33.37M |
| Basic EPS | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.36 | -1.22 | -1.45 | -0.95 |
Balance sheet
| Line item | 2023 | 2024 |
|---|---|---|
| Total current assets | 398.56M | 389.93M |
| Cash & ST investments | 390.90M | 385.37M |
| Inventory | -- | -- |
| Total assets | 444.11M | 441.89M |
| Total current liabilities | 18.22M | 36.18M |
| Short-term debt | 1.78M | 1.93M |
| Long-term debt | -- | -- |
| Total liabilities | 34,260,000.00 | 50,295,000.00 |
| Total equity | 409.85M | 391.60M |
| Retained earnings | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 289.40M | 177.75M |
| Cash & ST investments | -- | -- | 286.46M | 168.02M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 290.58M | 183.14M |
| Total current liabilities | -- | -- | 33.11M | 12.45M |
| Short-term debt | -- | -- | -- | 2.44M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 33,112,000.00 | 14,344,000.00 |
| Total equity | -- | -- | 257.46M | 168.80M |
| Retained earnings | -- | -- | -- | -24.58M |
Cash flow
| Line item | 2023 | 2024 |
|---|---|---|
| Operating cash flow | -93.00M | -125.81M |
| Depreciation & amortization | 2.38M | 2.40M |
| Free cash flow | -93.81M | -126.16M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 35.97M | 123.08M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -45.01M | -38.64M | -32.56M | -31.92M |
| Depreciation & amortization | 606.00K | 601.00K | 125.00K | 207.00K |
| Free cash flow | -45.04M | -38.68M | -32.58M | -31.94M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 98.64M | 44.30M | 248.47M | 168.02M |
Returns & efficiency
| Line item | 2023 | 2024 |
|---|---|---|
| ROE %i | -25.90 | -40.85 |
| ROA %i | -23.90 | -36.95 |
| ROIC %i | -27.70 | -43.36 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 21.87 | 10.78 |
| Quick ratioi | 21.45 | 10.65 |
| Debt / assetsi | 4.01 | 3.63 |
| LT debt / equityi | 3.91 | 3.60 |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -- | -- | -- | -- |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 8.74 | 14.28 |
| Quick ratioi | -- | -- | 8.65 | 13.91 |
| Debt / assetsi | -- | -- | 0.00 | 2.37 |
| LT debt / equityi | -- | -- | -- | 1.12 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-08 10:00:16 · For reference only, not investment advice and not tailored to your situation.